Все последние статьи, опубликованные на JAMA перед отправкой в печать Дискуссионная группа https://t.me/Medical_Professionals_Forum Свяжитесь с нами https://t.me/Contact_Updates_in_Medicine_Bot
This channel is part of the discussion
JAMA (Journal of the American Medical Association) appears in 17 event pages on TGListError in Text In the Images in Neurology titled “Aberrant Left-to-Right Fusion of the Oculomotor Nerve,” published on May 26, 2026, there was an error in the units of measure provided in the second sentence of the first paragraph. The sentence should have read, “On examination,…
Gefurulimab and Generalized Myasthenia Gravis This randomized clinical trial compares the novel dual-binding nanobody gefurulimab vs placebo for treating anti–acetylcholine receptor antibody–positive generalized myasthenia gravis.
Lessons From a Community-Designed Meal Program for Heart Failure The ambitious new trial by Eberly et al reports positive changes in health care utilization and clinical outcomes among patients with heart failure (HF) in Navajo Nation receiving a medically tailored meal…
Error in the Strengths and Limitations In the Original Investigation titled “Amateur Soccer Heading and Acute Elevations in Blood-Based p-Tau217 and S100B,” published online on May 18, 2026, there was an error in the Strengths and Limitations section regarding a biomarker…
Clinician Moral Injury and Immigration Policy Since January 2025, this country has undertaken what is likely among the most expansive immigration enforcement agendas in modern US history. Immigration policy has focused on aggressive enforcement tactics rather than integration…
First Effective Nanobody in Myasthenia Gravis Therapy In generalized myasthenia gravis (gMG), a continuously increasing spectrum of immunomodulatory agents with different mechanisms of action have been studied, including T- and B-cell directed drugs and drugs acting on…